The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...

Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over ...

Edwards Lifesciences stock surged Friday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences reported Street-beating Q2 results, upping the lower end of its full-year sales guidance.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

Heart Valve Replaced Without Surgery Through Arm Artery - First Ever Percutaneous Trans-Axillary TAVI in India ...